Tenax Therapeutics (TENX) Profit After Tax (2010 - 2026)

Tenax Therapeutics has reported Profit After Tax for 17 years, with the latest figure at -$17.8 million in Q2 2026.

• Profit After Tax for Q2 2026 came in at -$17.8 million, down 64.13% year-over-year; the trailing twelve-month figure through Jun 2026 was -$64.8 million (down 105.9% YoY), and the FY2025 annual result was -$52.6 million, down 198.83% from the prior year.
• Profit After Tax slipped to -$17.8 million in Q2 2026, from -$15.7 million in the prior quarter.
• Over five years, Profit After Tax peaked at $2.9 million in Q3 2022 and troughed at -$17.8 million in Q2 2026.
• A 5-year average of -$6.5 million and a median of -$3.9 million in 2024 frame the typical range for Profit After Tax.
• The widest annual swing landed in 2022, when Profit After Tax jumped 104.13%; it then plunged 578.5% in 2023.
• A 5-year view of Profit After Tax shows it stood at $2.5 million in 2022, then plunged by 578.5% to -$12.2 million in 2023, then surged by 48.61% to -$6.3 million in 2024, then tumbled by 147.33% to -$15.5 million in 2025, then slipped by 14.86% to -$17.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$17.8 million in Q2 2026, -$15.7 million in Q1 2026, and -$15.5 million in Q4 2025.